End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.83 MYR | -0.60% | +2.47% | -7.78% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company has insufficient levels of profitability.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Most analysts recommend that the stock should be sold or reduced.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-7.78% | 1.39B | B | ||
+11.84% | 27.79B | B+ | ||
-32.98% | 2.98B | B- | ||
-15.97% | 2.52B | C+ | ||
+11.90% | 2.34B | - | A- | |
-1.11% | 1.91B | B | ||
-13.37% | 1.83B | - | ||
-0.38% | 1.27B | - | ||
+4.01% | 1.13B | - | ||
+13.51% | 1.12B | C |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TOPGLOV Stock
- Ratings Top Glove Corporation Bhd.